New outcomes data demonstrating prolonged survival for inoperable pancreatic cancer patients presented at leading radiation oncology meeting
A multi-center study demonstrated improved overall survival and quality of life for inoperable pancreatic cancer patients treated with MRIdian SMART, with a median survival of 26 months. The treatment showed low rates of major adverse events and was more effective than standard radiation therapy.